Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Causal associations between both psoriasis and psoriatic arthritis and multiple autoimmune diseases: a bidirectional two-sample Mendelian randomization study

Duan K., Wang J., Chen S., Chen T., Wang J., Wang S.

Prospective Study on Neuroinflammation, Autoimmune Research, published in Front Immunol (2024) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Front Immunol (2024)
Reported sample size
—
Source database
Europe PMC
PMID
39119335
PMCID
PMC11306030
DOI
10.3389/fimmu.2024.1422626
Citations
5

Abstract (original English)

Background Numerous observational studies have identified associations between both psoriasis (PsO) and psoriatic arthritis (PsA), and autoimmune diseases (AIDs); however, the causality of these associations remains undetermined. Methods We conducted a bidirectional two-sample Mendelian Randomization study to identify causal associations and directions between both PsO and PsA and AIDs, such as systemic lupus erythematosus (SLE), Crohn's disease (CD), ulcerative colitis (UC), multiple sclerosis (MS), uveitis, bullous pemphigoid (BP), Hashimoto's thyroiditis (HT), rheumatoid arthritis (RA), vitiligo, and ankylosing spondylitis (AS). The causal inferences were drawn by integrating results from four regression models: Inverse Variance Weighting (IVW), MR-Egger, Weighted Median, and Maximum Likelihood. Furthermore, we performed sensitivity analyses to confirm the reliability of our findings. Results The results showed that CD [IVW odds ratio (OR IVW ), 1.11; 95% confidence interval (CI), 1.06-1.17; P = 8.40E-06], vitiligo (OR IVW , 1.16; 95% CI, 1.05-1.28; P = 2.45E-03) were risk factors for PsO, while BP may reduce the incidence of PsO (OR IVW , 0.91; 95% CI, 0.87-0.96; P = 1.26E-04). CD (OR IVW , 1.07; 95% CI, 1.02-1.12; P = 0.01), HT (OR IVW , 1.23; 95% CI, 1.08-1.40; P = 1.43E-03), RA (OR IVW , 1.11; 95% CI, 1.02-1.21, P = 2.05E-02), AS (OR IVW , 2.18; 95% CI, 1.46-3.27; P = 1.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansArthritis, PsoriaticPsoriasisAutoimmune DiseasesGenetic Predisposition to DiseasePolymorphism, Single NucleotideMendelian Randomization Analysis

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research